Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Transplant. 2010 Jul-Aug;24(4):E103-8. doi: 10.1111/j.1399-0012.2009.01179.x.

The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation.

Author information

  • 1Division of Transplant Surgery, University of Colorado at Denver and Health Sciences Center, Department of Anesthesia, Aurora, CO 800451, USA. michael.zimmerman@ucdenver.edu

Abstract

INTRODUCTION:

Cancer recurrence following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) is a significant obstacle in up to 10-20% of recipients. Recent evidence suggests that anti-CD3 antibody (OKT3) therapy may be associated with increased rates of HCC recurrence.

METHODS:

At the University of Colorado Transplant Center, 173 patients underwent OLT for end-stage liver disease with concomitant HCC between 1997 and 2008. Nine clinical and pathologic variables were analyzed to test the association between OKT3 therapy for steroid-resistant rejection (SRR) and HCC recurrence-free survival.

RESULTS:

Overall, the rate of HCC recurrence in this cohort was low and comparable across treatment groups (8.7%). Multivariate analysis reveals that increasing tumor diameter and differentiation have a negative impact on HCC recurrence-free survival.

CONCLUSIONS:

While several pathologic variables appear to influence outcome, we found no association between OKT3 therapy for SRR and HCC recurrence or survival.

© 2009 John Wiley & Sons A/S.

PMID:
20030681
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk